{
    "2018-01-29": [
        [
            {
                "time": "",
                "original_text": "贝达药业：预计2017年净利润同比下降20%-40%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利润",
                        "同比下降",
                        "2017年"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业:艾德生物液体活检获批,埃克替尼为最大受益靶向药",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "艾德生物",
                        "液体活检",
                        "埃克替尼",
                        "获批",
                        "靶向药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}